IMNR - Immune Response Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Stopforth who wrote (15)	12/14/1996 5:42:00 PM
From: Jphn Murray	of 1510

John, I came across the following entry in Barron's Market Watch Department: AutoImmune (AIMM-NNM) by UBS Securities (13 3/8, Nov. 25) Buy. The company's two lead products, Colloral for rheumatoid arthritis and Myloral for multiple sclerosis, are in Phase II and Phase III trials, respectively, and data regarding each should be available in the second quarter of 1997. Prior clinical data have been positive, and our conversations with certain investigators fuel our optimism about the outcome of ongoing trials. John Murray

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next